A detailed history of Stem Point Capital LP transactions in Immatics N.V. stock. As of the latest transaction made, Stem Point Capital LP holds 449,735 shares of IMTX stock, worth $3.19 Million. This represents 1.54% of its overall portfolio holdings.

Number of Shares
449,735
Previous 502,207 10.45%
Holding current value
$3.19 Million
Previous $5.84 Billion 12.07%
% of portfolio
1.54%
Previous 1.71%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.93 - $12.92 $573,518 - $677,938
-52,472 Reduced 10.45%
449,735 $5.13 Billion
Q2 2024

Aug 13, 2024

BUY
$9.78 - $13.49 $100,548 - $138,690
10,281 Added 2.09%
502,207 $5.84 Billion
Q1 2024

May 13, 2024

SELL
$10.23 - $12.94 $5.4 Million - $6.84 Million
-528,288 Reduced 51.78%
491,926 $5.17 Billion
Q4 2023

Feb 12, 2024

BUY
$7.36 - $10.89 $7.51 Million - $11.1 Million
1,020,214 New
1,020,214 $10.7 Billion

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $541M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Stem Point Capital LP Portfolio

Follow Stem Point Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stem Point Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Stem Point Capital LP with notifications on news.